Literature DB >> 19496324

Site-specific degradation of myelin basic protein by the proteasome.

A A Belogurov1, N A Ponomarenko, V M Govorun, A G Gabibov, A V Bacheva.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19496324     DOI： 10.1134/s1607672909020033

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  15 in total

1.  Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings.

Authors:  Alexei F Kisselev; Daniel Kaganovich; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2002-04-01       Impact factor: 5.157

2.  [Multiple forms of the proteasomes and some approaches to their separation].

Authors:  E B Abramova; T M Astakhova; P A Erokhov; N P Sharova
Journal:  Izv Akad Nauk Ser Biol       Date:  2004 Mar-Apr

3.  Substrate specificity of catalytic autoantibodies in neurodegenerative processes.

Authors:  A A Belogurov; I N Kurkova; V K Misikov; S V Suchkov; G B Telegin; A I Alekhine; N G Goncharov; V D Knorre; A G Gabibov; N A Ponomarenko
Journal:  Dokl Biochem Biophys       Date:  2007 Mar-Apr       Impact factor: 0.788

4.  Myelin basic protein, an autoantigen in multiple sclerosis, is selectively processed by human trypsin 4.

Authors:  Péter Medveczky; József Antal; András Patthy; Katalin Kékesi; Gábor Juhász; László Szilágyi; László Gráf
Journal:  FEBS Lett       Date:  2005-12-29       Impact factor: 4.124

5.  Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D.

Authors:  L B Pritzker; S Joshi; J J Gowan; G Harauz; M A Moscarello
Journal:  Biochemistry       Date:  2000-05-09       Impact factor: 3.162

6.  Catalytic antibodies in clinical and experimental pathology: human and mouse models.

Authors:  Natalya A Ponomarenko; Oxana M Durova; Ivan I Vorobiev; Elena S Aleksandrova; Georgy B Telegin; Olga G Chamborant; Lyudmila L Sidorik; Sergei V Suchkov; Zemfira S Alekberova; Nikolay V Gnuchev; Alexander G Gabibov
Journal:  J Immunol Methods       Date:  2002-11-01       Impact factor: 2.303

Review 7.  Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain.

Authors:  K E Schaecher; D C Shields; N L Banik
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

8.  Metal-dependent hydrolysis of myelin basic protein by IgGs from the sera of patients with multiple sclerosis.

Authors:  Dar'ya I Polosukhina; Tat'yana G Kanyshkova; Boris M Doronin; Olga B Tyshkevich; Valentina N Buneva; Alexey N Boiko; Evgenii I Gusev; Georgy A Nevinsky; Olga O Favorova
Journal:  Immunol Lett       Date:  2005-11-15       Impact factor: 3.685

9.  Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope.

Authors:  Abdiwahab A Musse; Joan M Boggs; George Harauz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-09       Impact factor: 11.205

10.  Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

Authors:  M Orlowski; C Cardozo; C Michaud
Journal:  Biochemistry       Date:  1993-02-16       Impact factor: 3.162
View more
  2 in total

1.  Association with proteasome determines pathogenic threshold of polyglutamine expansion diseases.

Authors:  Meewhi Kim; Ilya Bezprozvanny
Journal:  Biochem Biophys Res Commun       Date:  2020-12-25       Impact factor: 3.575

2.  Glatiramer acetate and nanny proteins restrict access of the multiple sclerosis autoantigen myelin basic protein to the 26S proteasome.

Authors:  Ekaterina Kuzina; Anna Kudriaeva; Ivan Smirnov; Michael V Dubina; Alexander Gabibov; Alexey Belogurov
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.